News & Updates
Filter by Specialty:

Can mouthwash cut COVID-19 salivary viral load?
In COVID-19 patients who had mild or no symptoms, the use of 0.05% cetylpyridinium chloride (CPC) and 0.01% on-demand aqueous chlorine dioxide (ACD) mouthwashes did not lead to a reduction in SARS-CoV-2 salivary viral load.
Can mouthwash cut COVID-19 salivary viral load?
23 Jul 2024
Acute benign myositis may occur in kids with flu infection
Children with influenza A virus infection are susceptible to acute benign myositis (ABM), with most patients showing clinical characteristics consistent with postfebrile myalgia, reports a study.
Acute benign myositis may occur in kids with flu infection
21 Jul 2024
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
Evaluation and treatment rates of patients with chronic hepatitis B (CHB) remain poor worldwide and differ by sex and race or ethnicity, reports a real-world study.
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
19 Jul 2024
Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease
In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).
Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease
18 Jul 2024
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.